At the Beacon Angels meeting on May 14, 2024, we conducted the following business.

We entertained funding presentations from the following:

• Relavo, developing a self-disinfecting connection device for kidney failure patients to receive peritoneal dialysis (PD) safely and at home; and
• EMBioSys, developing therapeutic wearable garments to treat solid metastatic cancers with low level induced electric fields (iEFs).

We also heard Beacon portfolio updates and follow-up presentations as follows:

• QSM Diagnostic (Edgar Goluch), selling diagnostic mail-in kits for veterinarians rapidly and accurately to diagnose bacterial infections in pets; and
• Zeptive, selling patented battery-powered and wireless vape/smoke & safety sensors for schools to detect risky behavior without cameras.

Members reported on pending and closed funding rounds, by Series number:

• 126 myBiometry developing an advanced early-warning system for asthma attacks.
• 112B Theromics, developing tumor-targeting therapies;
• 116B Realplay, providing video highlights for youth sports; and
• 122 GelMEDIX improving drug delivery for the eye.

Members reported on companies in due diligence:

• AI Lean; and
• AGED Diagnostics.